Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 64.60
-1.00 (-1.52%)
Aug 21, 2026, 5:31 PM CET
Basilea Pharmaceutica AG Financials Overview
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 247.42 | 232.38 | 208.54 | 157.63 | 147.77 | 148.12 |
Revenue Growth | 6.47% | 11.43% | 32.30% | 6.68% | -0.24% | 16.06% |
Gross Profit Gross Profit Growth | 95.27 | 87.16 | 92.72 | 52.99 | 49.36 | 30.89 |
Operating Income Operating Income Growth | 59.88 | 52.25 | 61.7 | 21.91 | 20.81 | 3.01 |
Net Income Net Income Growth | 52.38 | 40.24 | 77.59 | 10.45 | 12.15 | -6.83 |
Earnings Per Share EPS Growth | 4.01 | 3.14 | 5.82 | 0.86 | 1.02 | -0.58 |
EPS Growth | 27.62% | -46.05% | 577.28% | -15.69% | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Japan Japan Growth | 86.6 | 69.6 | 59.6 | 64 | 56.5 |
Ireland Ireland Growth | 78.1 | 93.7 | 68.7 | 41.3 | 62.1 |
USA USA Growth | 37 | 12.3 | 6.1 | 9.8 | 14.5 |
Uruguay Uruguay Growth | 8.7 | 12.1 | 10.2 | 7.4 | 3.4 |
China China Growth | 6.7 | 2.3 | 2.3 | 0.1 | - |
Other Other Growth | 15.3 | 18.5 | - | 0.6 | 0.7 |
Total Total Growth | 232.4 | 208.5 | 157.6 | 147.8 | 148.1 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 173.05 | 159.8 | 120.71 | 59.93 | 84.66 | 148.7 |
Total Debt Total Debt Growth | 83.44 | 89.22 | 111.67 | 128.61 | 187.14 | 218.96 |
Net Cash (Debt) Net Cash Growth | 89.61 | 70.58 | 9.04 | -68.67 | -102.48 | -70.26 |
Net Cash Growth | 26.96% | 680.74% | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 6.56 | 5.16 | 0.65 | -5.66 | -8.58 | -6.01 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 58.01 | 62.09 | 74.36 | 14.25 | 7.06 | -32.02 |
Capital Expenditures CapEx Growth | -2.71 | -2.62 | -1.71 | -0.81 | -3.14 | -0.58 |
Free Cash Flow Free Cash Flow Growth | 55.3 | 59.47 | 72.65 | 13.43 | 3.92 | -32.6 |
Free Cash Flow Growth | -7.01% | -18.14% | 440.89% | 242.83% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 38.51% | 37.51% | 44.46% | 33.62% | 33.40% | 20.86% |
Operating Margin | 24.20% | 22.48% | 29.59% | 13.90% | 14.09% | 2.03% |
Pretax Margin | 23.72% | 19.74% | 28.90% | 6.64% | 8.19% | -4.59% |
Profit Margin | 21.17% | 17.32% | 37.21% | 6.63% | 8.22% | -4.61% |
FCF Margin | 22.35% | 25.59% | 34.84% | 8.52% | 2.65% | -22.01% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.11 | 16.70 | 6.46 | 40.47 | 44.94 | - |
Forward PE | 16.81 | 13.26 | 10.63 | 15.17 | 98.35 | 225.87 |
P/FCF Ratio | 14.49 | 11.30 | 6.90 | 31.48 | 139.32 | - |
PS Ratio | 3.24 | 2.89 | 2.40 | 2.68 | 3.69 | 3.27 |